Medicinal chemistry and drug design
3 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- LATVIJAS ORGANISKAS SINTEZES INSTITUTS
Latvia's premier medicinal chemistry and drug discovery institute, combining organic synthesis with structural biology for pharmaceutical R&D across Europe.
“Core competency spanning INTEGRATE, CARTNET, SPRINGBOARD, IT-DED3, PELICO, ALISE, BATCure, and EU-OPENSCREEN-DRIVE — covering antibacterials, anti-cancer conjugates, and ophthalmic drug discovery.”
PrimaryLV18 projects - ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE
Ukrainian medicinal chemistry SME specializing in compound libraries, photopharmacology, bioisostere design, and AI-driven drug discovery.
“Core contributor across PELICO, SAFER, AEGIS, ALISE, and BENOVELTY — all centered on designing bioactive compounds for therapeutic use.”
PrimarySMEUA7 projects - FUNDACION UNIVERSITARIA SAN PABLO-CEU
Madrid-based private university specializing in medicinal chemistry, drug design for cancer therapeutics, and hosting international research fellowships.
“Projects DUALITY (dual-target enzyme inhibitors), PROTACs (cancer-targeting PROTAC molecules), and MaGMa (metabolomics and therapeutic targets) all focus on rational drug design and synthesis.”
PrimaryES7 projects